TY - T1的慢性咳嗽、慢性疼痛的相关性的JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.02651 -2020欧元SP - 2002651 AU Arinze Johnmary t . AU - Verhamme凯蒂m . c . AU -卢伊克,安玛丽。非盟-斯特里克,布鲁诺AU -范·穆尔,乔伊斯·b·J . AU - Brusselle由于慢性咳嗽与慢性疼痛有共同的神经生物学机制和病理生理学机制，这两种临床疾病可能是相互关联的。因此，我们在鹿特丹研究(一项基于人群的大型前瞻性队列研究)中研究了成年受试者慢性咳嗽和慢性疼痛之间的关系。方法采用标准化问卷调查，慢性疼痛定义为持续时间长达6个月的疼痛，并按每周/每月或每天的疼痛频率分组。慢性咳嗽被描述为每天咳嗽至少持续3个月。纵向和横向关联是双向的。结果在7141名受试者中，54% (n=3888)报告基线时有慢性疼痛。每日慢性疼痛和慢性咳嗽的共同流行率为4.4%。与无慢性疼痛的受试者相比，有每日和每周/每月慢性疼痛的受试者慢性咳嗽更为普遍(13.8%和10.3% vs 8.2%， p;0.001)。校正潜在混杂因素后，普遍的慢性疼痛与慢性咳嗽的发生率显著相关(OR 1.47, 95% CI 1.08-1.99)。在患有每日慢性疼痛的受试者中(OR 1.49, 95% CI 1.06-2.11)，这种关联仍然显著，在患有每周/每月慢性疼痛的受试者中(OR 1.43, 95% CI 0.98-2.10)，尽管没有显著性影响，但效果估计相似。 After adjustment for covariables, subjects with chronic cough had a significant risk of developing chronic pain (OR 1.63, 95% CI 1.02–2.62) compared with those without chronic cough.Conclusion Chronic cough and chronic pain confer risk on each other among adult subjects, indicating that both conditions might share common risk factors and/or pathophysiologic mechanisms.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Arinze reports grants from MSD, outside the submitted work;.Conflict of interest: KV works for a research group who in the past received unconditional grants from Yamanouchi, Pfizer/Boehringer Ingelheim, Novartis, GSK none of which relate to the content of this work.Conflict of interest: Dr. Luik has nothing to disclose.Conflict of interest: Dr. Stricker has nothing to disclose.Conflict of interest: Dr. van Meurs has nothing to disclose.Conflict of interest: Dr. Brusselle reports personal fees from Astra Zeneca, personal fees from Boehringer-Ingelheim, personal fees from Chiesi, personal fees from Glaxo Smith Kline, personal fees from Novartis, personal fees from Sanofi, personal fees from Teva, grants from MSD, outside the submitted work;. ER -